ClinicalTrials.gg
Enrolling by invitationNCT06350981Updated Sep 9, 2026

Analgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion

A Phase 2/3 interventional study of Exparel and Bupivacain in Back Pain, Surgery-Complications and Narcotic Use, sponsored by Foundation for Orthopaedic Research and Education. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Foundation for Orthopaedic Research and Education · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 307 studies in Back Pain with a site in United States — 38 open to participants now, 51 under way, 4 of them phase 3. Back Pain · United States.

Planned enrollment
131st of 262
76 · median 76
Started
2024
with 18 others
Phase 2/3
3 of 307
1 open now
Primary completion
2027-01
later than 21 of 50 live
Registered
274th of 307
by date

Among the 307 studies in Back Pain with a site in United States, this one is the 131st largest by planned enrollment of the 262 interventional ones that give a count, is one of 19 that started in 2024, is one of 3 in phase 2/3, reaches primary completion later than 21 of the 50 other live ones, and was the 274th registered.

Back Pain

729 studies on the registry are indexed under Back Pain; 110 are open to participants now.

Browse Back Pain studies →

Open to participants now

38 of the 307 studies in Back Pain with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 307 studies in Back Pain with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trail is to to compare the efficacy of thoracolumbar interfascial plane block with Exparel vs with standard of care 0.25% Bupivacaine HCl in patients undergoing 1-3 level elective transforaminal lumbar interbody fusion. The investigators hypothesize that thoracolumbar interfascial plane block with Exparel will outperform standard of care (supplemented with interfascial plane block of 0.25% Bupivacaine HCl) with regards to pain reduction, narcotic use, length of hospital stay, time to mobilization with physical therapy, narcotic usage in the hospital, and post operative pain scores.

03

Conditions studied

  • Back Pain
  • Surgery-Complications
  • Narcotic Use
  • Physical Stress
  • Post Operative Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years or older,
  • Patients admitted to AHC for 1-3 level TLIF,
  • Patients who have given written ,
  • between 18-35 kg/m2,

Exclusion criteria

Exclusion Criteria:

  • Patients with known allergic reactions to standard of care analgesics,
  • Female patients who are pregnant
  • Patients with any previous lumbar spine instrumented surgery,
  • Chronic opioid use within 30 days prior to randomization that exceeds average ≥30 oral morphine equivalents/day,
  • Patients with known allergy to local anesthetics,
  • Patients with known or suspected to have neuromuscular disorders impairing neuromuscular blockade (e.g. myasthenia gravis).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Exparel TLIP Injection

    Subjects will receive 20 mL of EXPAREL 266mg mixed with 10 mL of 0.25% bupivacaine. A total of 30 mL of mixed solution is injected into the thoracolumbar interfacial plane.

    Drug: Exparel

  • Active comparator
    Bupivicaine HCL TLIP Injection

    Standard of care will consist of 0.25% Bupivacaine HCl TLIP injection. Subjects will receive 30 mL of the solution, injected into the thoracolumbar interfacial plane.

    Drug: Bupivacain

Interventions

06

What researchers measure

Primary outcomes

  1. Compare efficacy of thoracolumbar interfacial plane block with Exparel vs. standard of care (0.25% Bupivacaine HCL) is surgical subjects undergoing 1-3 level elective transforaminal lumbar interbody fusion.

    Data will be analyzed by randomized treatment group to determine efficacy. Superiority of treatment with EXPAREL compared with Bupivacaine hydrochloride will be determined using linear regression adjusting for Pain Catastrophizing Scale with treatment as main effect for the primary efficacy endpoint of area under the curve of the Numerical rating scale pain intensity scores from 0 to 72 hours post-surgery.

    Time frame: 0-72 hours post-operatively

Secondary outcomes

  1. Total Postsurgical opioid consumption

    The following data points will be recorded to further claim the investigators hypothesis of treatment with EXPAREL compared to Bupivacaine hydrochloride. • Total postsurgical opioid consumption in oral morphine equivalents (Oral morphine equivalents) from 0 to 76 hours post-surgery

    Time frame: 0-72 hours postoperatively

  2. Time to discharge

    collect hours of hospital stay

    Time frame: 0-72 hours postoperatively

  3. Time to ambulation

    collect time ambulated from surgery

    Time frame: 0-72 hours postoperatively

  4. Maximum ambulated distance

    Physical Therapy will document the distance subject could ambulate after surgery

    Time frame: 0-72 hours postoperatively

  5. Numeric Rating Pain Scale (Physical Therapy)

    Measure pain score (scale of 0-10 with 0 indicates no pain and 10 severe pain) during physical therapy (ambulation)

    Time frame: 0-72 hours postoperatively

  6. Numeric Rating Pain Scale

    Numerical rating scale pain intensity scores at 24hour, 36hour, 60hour, and 72hour from the end of surgery and again at the first clinic visit postoperatively (scale of 0-10 with 0 indicates no pain and 10 severe pain)

    Time frame: 0-72 hours with additional follow-up at 14 days (first clinic visit)

  7. Oswestry Disability Index (ODI)

    10 questions relating to function specific to low back pain given before surgery and collected at 14 day post op visit.

    Time frame: 0- 14 days postoperatively

  8. Pain Catastrophizing Scale (PCS)

    This scale measures thoughts and feelings that may be associated with pain. it is rated 0-5 with 0 indicating not at all, 1 indicating to a slight degree, 2 indicates a moderate degree, 3 indicates a great degree and 4 idicates all the time. There are 13 statements that are rated, the ratings are scored to determine where each subject falls in the scale.

    Time frame: 0-14 days postoperatively

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Jan 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Apr 8, 2024
StartActual
Apr 30, 2024
Primary completionEst.
Jan 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06350981
Lead sponsor
Foundation for Orthopaedic Research and Education
Responsible party
Sponsor
First posted
Apr 8, 2024
Start date
Apr 30, 2024
Primary completion
Jan 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

John Small, MD
principal investigator · Florida Orthopaedic Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion